USA-based tumor drug resistance specialist Deciphera Pharmaceuticals yesterday announced that its Qinlock (ripretinib) has been included in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred regimen for second-line gastrointestinal stromal tumor (GIST) patients intolerant to sunitinib. 15 March 2023
UK-based company that uses artificial intelligence (AI) in drug discovery Exscientia saw its shares edge up 2.8% to $6.86 in morning trading today, despite announcing that US pharma major Bristol Myers Squibb would not be taking up an option under an agreement with Celgene. 15 March 2023
The Phase I trial of XMT-2056 has been placed on clinical hold by the US Food and Drug Administration (FDA), said the drug’s developer, US clinical-stage biotech Mersana Therapeutics, whose shares fell over 2% to $4.6 in pre-market trading today 13 March 2023
Exenatide, a GLP-1 agonist sold under the brand names Byetta and Bydureon by AstraZeneca (LSE: AZN) as a type 2 diabetes drug, could be useful in another indication, a trial has found. 13 March 2023
Two American firms have agreed terms for the joint commercialization of the novel attention deficit/hyperactivity disorder (ADHD) candidate CTx-1301 (dexmethylphenidate). 13 March 2023
Provention Bio’s shares skyrocketed 262% to $24.27 in pre-market trading today, on the news that French pharma major Sanofi had made a takeover bid for the US biotech. 13 March 2023
Shares of US drug developer Intercept Pharmaceuticals closed almost 14% lower at $16.12 on Friday, after it revealed that the US regulator will hold an advisory committee meeting to review its re-submitted approval request for its investigational non-alcoholic steatohepatitis (NASH) treatment obeticholic acid (OCA). 13 March 2023
The US Food and Drug Administration (FDA) has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. 11 March 2023
Some $230 million has now been raised by Ring Therapeutics, a life sciences company founded by Flagship Pioneering with the aim of revolutionizing gene therapy with its commensal virome platform. 10 March 2023
Shares of MacroGenics were up 10.9% at $6.10 in early trading today, after the biopharmaceutical company revealed that it has entered into an agreement to sell its royalty interest on future global net sales of Tzield (teplizumab-mzwv) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million. 9 March 2023
Cambridge, USA-based clinical-stage biotech QurAlis Corporation has closed an oversubscribed $88 million Series B financing, bringing the total funds raised by the company0 to $143.5 million. 9 March 2023
UK biotech Redx Pharma added to its woes, announcing that top-line results of its Phase II program were not sufficient enough to support the development of its RXC004 treatment as a monotherapy. 8 March 2023
Italian drugmaker Chiesi and Swedish biotech Affibody have agreed a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using the latter company’s technology. 8 March 2023
The strategic venture capital unit of US healthcare giant Johnson & Johnson (NYSE: JNJ) has put its weight behind a $100 million boost for a new precision medicine company. 8 March 2023
Protagonist Therapeutics’ shares closed up a massive 52% at $23.09 yesterday, after it announced positive top-line results from the FRONTIER 1 Phase IIb clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis. 8 March 2023
US clinical-stage cancer biotech Volastra Therapeutics, which is focused on exploiting chromosomal instability (CIN), today announced completion of the in-licensing of Amgen’s sovilnesib (AMG650), an oral, first-in-class small molecule inhibitor of KIF18A. 7 March 2023
Shares of Aclaris Therapeutics closed down almost 45% at $7.07 yesterday, as the company said its zunsemetinib did not meet its primary and secondary efficacy endpoints in a Phase IIa study evaluating the investigational drug in patients with moderate to severe hidradenitis suppurativa. 7 March 2023
Shares of UK cell therapy specialist Adaptimmune Therapeutics and Cambridge, USA-based TCR² Therapeutics moved in opposite directions this morning, as they announced plans to merge. 6 March 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024